


Understanding the **BESPOKE CRC** study: Your path to confident cancer monitoring



The BESPOKE study¹ examined stage II/III colorectal cancer (CRC) patients using Signatera™ to monitor recurrence after treatment or surgery.


What is ctDNA?

- ctDNA (circulating tumor DNA) refers to fragments of tumor DNA found in your blood after cancer surgery or treatment.
- Signatera™ measures the presence of ctDNA in your blood and is meant to be used over time, to assess how your cancer may be responding to treatment, or if your cancer may be coming back.
- Signatera™ testing provides personalized information about your cancer, helping doctors tailor your treatment plan to optimize treatment outcomes.




What is the **BESPOKE** study?

The BESPOKE study included data gathered from hundreds of colorectal cancer patients and multiple hospital systems. The study set out to better understand if monitoring patients for the presence of molecular residual disease (MRD) using circulating tumor DNA (ctDNA) can help detect cancer recurrence earlier and help guide treatment decision making. As part of the study, patients were also asked to complete a HADS² questionnaire as it related to their MRD testing. Both ctDNA positive and ctDNA negative patients were included in the questionnaire results.



What was discovered in the first **BESPOKE** Patient Reported Outcome (PRO) analysis?



Significance of findings: The value of knowing



Tailoring treatment to you

Signatera™ is custom designed for each patient to help identify relapse earlier than standard of care tools.



Minimized anxiety, enhanced understanding

Understanding your Signatera™ results may provide peace of mind about your treatment path.

Why Signatera™?

Signatera™ is a unique blood test, personalized for each patient using their own tumor tissue. It is used to detect cancer recurrence earlier and treatment response better than standard of care tools.

A doctor may order Signatera™, along with other routine follow up exams to determine:

- If there are any signs of cancer remaining in the body
- If the treatment (ie chemotherapy, radiation, immune checkpoint inhibitors) is working
- If the cancer may be coming back

Take the next step

Talk with your doctor and see if Signatera™ is right for you

Visit us at natera.com/signaterapatient or by **scanning the QR code**



References

1. Kasi et al, Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study, as presented at 2024 Gastrointestinal (GI) Cancers Symposium
2. <https://pubmed.ncbi.nlm.nih.gov/6880820/>